CLINICAL TRIALS PROFILE FOR FLUDEOXYGLUCOSE F-18

All Clinical Trials for Fludeoxyglucose F-18

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001568 ↗	Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Moda	Completed	National Cancer Institute (NCI)	Phase 2	1997-02-01	Positron Emission Tomography (PET scanning) is performed using a total dose of less than 50 mRad per patient visit. Fludeoxyglucose F 18 (FDG) is injected intravenously over 2 min. Initial dynamic images will be obtained over the heart. Emission imaging will work from the midcervical region down to the perineal region. For CEA scanning, radiolabeled antibody, arcitumomab (IMMU-4), is injected intravenously over 5 min. A single photon emission computed tomography (SPECT) transmission scan is performed over the same regions as the emission scans. Total dose from transmission scans should be no more than 20 mRad per patient visit. Patients then undergo exploratory laparotomy performed by two surgeons, one blinded to the results of the CEA-Scan and PET scan. At the completion of all exploration, all identified disease is biopsied for pathologic analysis and any resectable disease is removed. Patients are followed every 3 months for 1 year, every 6 months for the second year, and then after 3 years.
NCT00004152 ↗	PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma	Completed	National Cancer Institute (NCI)	Phase 2	1999-02-01	RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease in patients who have stage III or stage IV melanoma.
NCT00004152 ↗	PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	1999-02-01	RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease in patients who have stage III or stage IV melanoma.
NCT00004867 ↗	Positron Emission Tomography in Determining Stage of Esophageal Cancer	Completed	National Cancer Institute (NCI)	N/A	1999-11-01	RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer.
NCT00004867 ↗	Positron Emission Tomography in Determining Stage of Esophageal Cancer	Completed	Alliance for Clinical Trials in Oncology	N/A	1999-11-01	RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer.
NCT00004891 ↗	PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery	Completed	National Cancer Institute (NCI)	N/A	1999-09-01	RATIONALE: Diagnostic procedures, such as PET and CT scans, may improve the ability to detect the extent of locally advanced primary rectal cancer and may also help to measure a patient's response to treatment. PURPOSE: This clinical trial is studying how well PET and CT scans detect residual or metastatic disease in patients with locally advanced primary rectal cancer that can be removed during surgery.

Clinical Trial Conditions for Fludeoxyglucose F-18

Condition Name

Condition Name for Fludeoxyglucose F-18
Intervention	Trials
Lymphoma	15
Lung Cancer	9
Breast Cancer	7
Plasma Cell Myeloma	5

Condition MeSH

Condition MeSH for Fludeoxyglucose F-18
Intervention	Trials
Carcinoma	32
Lymphoma	26
Lung Neoplasms	21
Sarcoma	17

Clinical Trial Locations for Fludeoxyglucose F-18

Trials by Country

Trials by Country for Fludeoxyglucose F-18
Location	Trials
Canada	57
Australia	8
Puerto Rico	6
Korea, Republic of	5
New Zealand	4

Trials by US State

Trials by US State for Fludeoxyglucose F-18
Location	Trials
California	60
Maryland	53
Ohio	49
New York	45
Illinois	45

Clinical Trial Progress for Fludeoxyglucose F-18

Clinical Trial Phase

Clinical Trial Phase for Fludeoxyglucose F-18
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	16
Phase 2/Phase 3	5

Clinical Trial Status

Clinical Trial Status for Fludeoxyglucose F-18
Clinical Trial Phase	Trials
Completed	70
Active, not recruiting	35
Recruiting	27

Clinical Trial Sponsors for Fludeoxyglucose F-18

Sponsor Name

Sponsor Name for Fludeoxyglucose F-18
Sponsor	Trials
National Cancer Institute (NCI)	129
University of Washington	8
M.D. Anderson Cancer Center	7

Sponsor Type

Sponsor Type for Fludeoxyglucose F-18
Sponsor	Trials
Other	155
NIH	131
Industry	27